AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Clinical Trials
3.7k
Trial Phases
6 Phases
Drug Approvals
31
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- Next
Clinical Trials
Distribution across different clinical trial phases (2748 trials with phase data)• Click on a phase to view related trials
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Other: Placebo
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1160
- Registration Number
- NCT07082738
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 114
- Registration Number
- NCT07081633
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳China-japan Friendship Hospital, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, China
A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary DiseaseHyperinflation
- Interventions
- Drug: Budesonide/Glycopyrronium/Formoterol FumarateDrug: PlaceboDevice: Metered dose inhaler
- First Posted Date
- 2025-07-20
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 56
- Registration Number
- NCT07073950
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Early-Line Treatment in Subjects With Multiple Myeloma
- Conditions
- Newly Diagnosed Multiple MyelomaRelapsed Refractory Multiple Myeloma
- Interventions
- Biological: GC012F (AZD0120)
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT07073547
- Locations
- 🇺🇸
Research site, New York, New York, United States
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
- Conditions
- Gastroesophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT07069712
- Locations
- 🇬🇧
Research Site, Headington, United Kingdom
- Prev
- 1
- 2
- 3
- 4
- 5
- 660
- Next
News
Bristol Myers Squibb Appoints AstraZeneca's Cristian Massacesi as New Chief Medical Officer
Bristol Myers Squibb has appointed Cristian Massacesi, M.D., former AstraZeneca Chief Medical Officer, as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025.
STRIDE Immunotherapy Achieves Unprecedented 19.6% Five-Year Survival Rate in Advanced Liver Cancer
A new exploratory analysis of the HIMALAYA phase III trial shows that 19.6% of patients with unresectable hepatocellular carcinoma treated with STRIDE immunotherapy remained alive after five years, compared to 9.4% with sorafenib.
AstraZeneca Announces $50 Billion US Investment Plan with Virginia Manufacturing Hub for Weight Management and Metabolic Drugs
AstraZeneca announces a $50 billion investment in the United States by 2030, with Virginia selected as the site for the company's largest single manufacturing facility investment globally.
Moderna Cancels mRNA Manufacturing Plant in Japan Amid Declining Vaccine Demand and Regulatory Uncertainty
Moderna has canceled plans to build an mRNA vaccine manufacturing plant at Shonan Health Innovation Park in Kanagawa Prefecture due to weak global vaccine demand and challenging business conditions.
NIHR Pilots 'Just in Time' Clinical Trial Initiative for Pancreatic Cancer Using Pembrolizumab-Olaparib Combination
The National Institute for Health and Care Research is piloting a 'Just in Time' scheme that could reduce clinical trial setup time from months to days, potentially improving patient access to trials closer to home.
Lisata Therapeutics Reports Promising 60% Response Rate in Pancreatic Cancer Trial with Certepetide
Lisata Therapeutics and WARPNINE completed enrollment in the Phase 1b/2a iLSTA trial evaluating certepetide in combination with standard-of-care therapy for locally advanced pancreatic ductal adenocarcinoma.
AstraZeneca Partners with CSPC for AI-Driven Drug Discovery Platform to Develop Novel Oral Therapies
AstraZeneca has entered into a strategic partnership with CSPC to leverage artificial intelligence-driven drug discovery capabilities for accelerated development of novel oral therapeutic candidates.
Sino Biopharm Acquires LaNova Medicines for $950M, Expanding Innovative Drug Pipeline
Sino Biopharm announced acquisition of remaining 95.09% stake in LaNova Medicines for up to $950 million, making it a wholly owned subsidiary.
AstraZeneca's Anselamimab Fails Primary Endpoint in Phase III AL Amyloidosis Trial, Shows Promise in Patient Subgroup
AstraZeneca's CARES Phase III clinical programme evaluating anselamimab in patients with Mayo stages IIIa and IIIb light chain amyloidosis did not achieve statistical significance for the primary endpoint of time to all-cause mortality and cardiovascular hospitalizations.
Sino Biopharmaceutical Acquires LaNova Medicines for $951 Million, Targeting PD-1xVEGF Cancer Therapies
Sino Biopharmaceutical announced plans to acquire LaNova Medicines for up to $951 million, with a net payment of approximately $500 million after accounting for cash holdings.